Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 3591 entries
Sorted by: Best Match Show Resources per page
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond.

Drugs in context

Prasad-Reddy L, Isaacs D.
PMID: 26213556
Drugs Context. 2015 Jul 09;4:212283. doi: 10.7573/dic.212283. eCollection 2015.

The prevalence of type 2 diabetes is increasing at an astounding rate. Many of the agents used to treat type 2 diabetes have undesirable adverse effects of hypoglycemia and weight gain. Glucagon-like peptide-1 (GLP-1) receptor agonists represent a unique...

Cite
Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:212283doi: 10.7573/dic.212283.
Prasad-Reddy, L., & Isaacs, D. (2015). A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs in context, 4212283. https://doi.org/10.7573/dic.212283
Prasad-Reddy, Lalita, and Isaacs, Diana. "A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond." Drugs in context vol. 4 (2015): 212283. doi: https://doi.org/10.7573/dic.212283
Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015 Jul 09;4:212283. doi: 10.7573/dic.212283. eCollection 2015. PMID: 26213556; PMCID: PMC4509428.
Copy Download .nbib Format: NLM
Prolonged Remission of Diabetes by Regeneration of β Cells in Diabetic Mice Treated with Recombinant Adenoviral Vector Expressing Glucagon-like Peptide-1.

Molecular therapy : the journal of the American Society of Gene Therapy

Liu MJ, Shin S, Li N, Shigihara T, Lee YS, Yoon JW, Jun HS.
PMID: 28182934
Mol Ther. 2007 Jan;15(1):86-93. doi: 10.1038/sj.mt.6300005. Epub 2016 Dec 08.

Type 1 diabetes results from insulin deficiency caused by destruction of pancreatic β cells. Glucagon-like peptide (GLP)-1 stimulates β cell growth and differentiation. To determine whether continuous expression of GLP-1 in vivo can regenerate β cells and remit type...

Cite
Liu MJ, Shin S, Li N, et al. Prolonged Remission of Diabetes by Regeneration of β Cells in Diabetic Mice Treated with Recombinant Adenoviral Vector Expressing Glucagon-like Peptide-1. Mol Ther. 2016;15(1):86-93doi: 10.1038/sj.mt.6300005.
Liu, M. J., Shin, S., Li, N., Shigihara, T., Lee, Y. S., Yoon, J. W., & Jun, H. S. (2007). Prolonged Remission of Diabetes by Regeneration of β Cells in Diabetic Mice Treated with Recombinant Adenoviral Vector Expressing Glucagon-like Peptide-1. Molecular therapy : the journal of the American Society of Gene Therapy, 15(1), 86-93. https://doi.org/10.1038/sj.mt.6300005
Liu, Meng-Ju, et al. "Prolonged Remission of Diabetes by Regeneration of β Cells in Diabetic Mice Treated with Recombinant Adenoviral Vector Expressing Glucagon-like Peptide-1." Molecular therapy : the journal of the American Society of Gene Therapy vol. 15,1 (2007): 86-93. doi: https://doi.org/10.1038/sj.mt.6300005
Liu MJ, Shin S, Li N, Shigihara T, Lee YS, Yoon JW, Jun HS. Prolonged Remission of Diabetes by Regeneration of β Cells in Diabetic Mice Treated with Recombinant Adenoviral Vector Expressing Glucagon-like Peptide-1. Mol Ther. 2007 Jan;15(1):86-93. doi: 10.1038/sj.mt.6300005. Epub 2016 Dec 08. PMID: 28182934.
Copy Download .nbib Format: NLM
Effect of Roux-en-Y gastric bypass surgery on intestinal Akkermansia muciniphila.

World journal of gastrointestinal surgery

Yan M, Song MM, Bai RX, Cheng S, Yan WM.
PMID: 27152136
World J Gastrointest Surg. 2016 Apr 27;8(4):301-7. doi: 10.4240/wjgs.v8.i4.301.

AIM: To investigated changes in intestinal Akkermansia muciniphila (A. muciniphila) and explored the mechanism underlying the therapeutic effects of Roux-en-Y gastric bypass (RYGB) surgery on type 2 diabetes in diabetic Goto-Kakizaki (GK) rats.METHODS: Male diabetic GK rats (n =...

Cite
Yan M, Song MM, Bai RX, et al. Effect of Roux-en-Y gastric bypass surgery on intestinal Akkermansia muciniphila. World J Gastrointest Surg. 2016;8(4):301-7doi: 10.4240/wjgs.v8.i4.301.
Yan, M., Song, M. M., Bai, R. X., Cheng, S., & Yan, W. M. (2016). Effect of Roux-en-Y gastric bypass surgery on intestinal Akkermansia muciniphila. World journal of gastrointestinal surgery, 8(4), 301-7. https://doi.org/10.4240/wjgs.v8.i4.301
Yan, Ming, et al. "Effect of Roux-en-Y gastric bypass surgery on intestinal Akkermansia muciniphila." World journal of gastrointestinal surgery vol. 8,4 (2016): 301-7. doi: https://doi.org/10.4240/wjgs.v8.i4.301
Yan M, Song MM, Bai RX, Cheng S, Yan WM. Effect of Roux-en-Y gastric bypass surgery on intestinal Akkermansia muciniphila. World J Gastrointest Surg. 2016 Apr 27;8(4):301-7. doi: 10.4240/wjgs.v8.i4.301. PMID: 27152136; PMCID: PMC4840169.
Copy Download .nbib Format: NLM
Accumulation of intestinal tissue 3-deoxyglucosone attenuated GLP-1 secretion and its insulinotropic effect in rats.

Diabetology & metabolic syndrome

Zhang L, Song X, Zhou L, Liang G, Xu H, Wang F, Huang F, Jiang G.
PMID: 27956941
Diabetol Metab Syndr. 2016 Nov 29;8:78. doi: 10.1186/s13098-016-0194-9. eCollection 2016.

BACKGROUND: Our recent findings support the idea that 3-deoxyglucosone (3DG), a dietary composition, has been suggested as an independent factor for the development of prediabetes. Secretion of glucagon-like peptide-1 (GLP-1) has been suggested to be impaired in T2DM and...

Cite
Zhang L, Song X, Zhou L, et al. Accumulation of intestinal tissue 3-deoxyglucosone attenuated GLP-1 secretion and its insulinotropic effect in rats. Diabetol Metab Syndr. 2016;8:78doi: 10.1186/s13098-016-0194-9.
Zhang, L., Song, X., Zhou, L., Liang, G., Xu, H., Wang, F., Huang, F., & Jiang, G. (2016). Accumulation of intestinal tissue 3-deoxyglucosone attenuated GLP-1 secretion and its insulinotropic effect in rats. Diabetology & metabolic syndrome, 878. https://doi.org/10.1186/s13098-016-0194-9
Zhang, Lurong, et al. "Accumulation of intestinal tissue 3-deoxyglucosone attenuated GLP-1 secretion and its insulinotropic effect in rats." Diabetology & metabolic syndrome vol. 8 (2016): 78. doi: https://doi.org/10.1186/s13098-016-0194-9
Zhang L, Song X, Zhou L, Liang G, Xu H, Wang F, Huang F, Jiang G. Accumulation of intestinal tissue 3-deoxyglucosone attenuated GLP-1 secretion and its insulinotropic effect in rats. Diabetol Metab Syndr. 2016 Nov 29;8:78. doi: 10.1186/s13098-016-0194-9. eCollection 2016. PMID: 27956941; PMCID: PMC5129672.
Copy Download .nbib Format: NLM
In vitro effect of glucagon-like peptide-1 (7-36)amide, oxyntomodulin, vasoactive intestinal peptide and somatostatin on gastric acid and pepsinogen secretion.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]

Ben-Hamida A, Houssein AA, Man WK, Spencer J.
PMID: 27518026
Inflamm Res. 1997 Mar;46:105-6. doi: 10.1007/s000110050122.

No abstract available.

Cite
Ben-Hamida A, Houssein AA, Man WK, et al. In vitro effect of glucagon-like peptide-1 (7-36)amide, oxyntomodulin, vasoactive intestinal peptide and somatostatin on gastric acid and pepsinogen secretion. Inflamm Res. 1997;46:105-6doi: 10.1007/s000110050122.
Ben-Hamida, A., Houssein, A. A., Man, W. K., & Spencer, J. (1997). In vitro effect of glucagon-like peptide-1 (7-36)amide, oxyntomodulin, vasoactive intestinal peptide and somatostatin on gastric acid and pepsinogen secretion. Inflammation research : official journal of the European Histamine Research Society ... [et al.], 46105-6. https://doi.org/10.1007/s000110050122
Ben-Hamida, A, et al. "In vitro effect of glucagon-like peptide-1 (7-36)amide, oxyntomodulin, vasoactive intestinal peptide and somatostatin on gastric acid and pepsinogen secretion." Inflammation research : official journal of the European Histamine Research Society ... [et al.] vol. 46 (1997): 105-6. doi: https://doi.org/10.1007/s000110050122
Ben-Hamida A, Houssein AA, Man WK, Spencer J. In vitro effect of glucagon-like peptide-1 (7-36)amide, oxyntomodulin, vasoactive intestinal peptide and somatostatin on gastric acid and pepsinogen secretion. Inflamm Res. 1997 Mar;46:105-6. doi: 10.1007/s000110050122. PMID: 27518026.
Copy Download .nbib Format: NLM
The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial.

Diabetes therapy : research, treatment and education of diabetes and related disorders

Linjawi S, Bode BW, Chaykin LB, Courrèges JP, Handelsman Y, Lehmann LM, Mishra A, Simpson RW.
PMID: 27943107
Diabetes Ther. 2017 Feb;8(1):101-114. doi: 10.1007/s13300-016-0218-3. Epub 2016 Dec 10.

INTRODUCTION: The progressive nature of type 2 diabetes necessitates treatment intensification. This often involves intensification with oral antidiabetic drugs (OADs) initially, followed by other agents, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), with the majority of patients eventually requiring...

Cite
Linjawi S, Bode BW, Chaykin LB, et al. The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial. Diabetes Ther. 2016;8(1):101-114doi: 10.1007/s13300-016-0218-3.
Linjawi, S., Bode, B. W., Chaykin, L. B., Courrèges, J. P., Handelsman, Y., Lehmann, L. M., Mishra, A., & Simpson, R. W. (2017). The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial. Diabetes therapy : research, treatment and education of diabetes and related disorders, 8(1), 101-114. https://doi.org/10.1007/s13300-016-0218-3
Linjawi, Sultan, et al. "The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial." Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 8,1 (2017): 101-114. doi: https://doi.org/10.1007/s13300-016-0218-3
Linjawi S, Bode BW, Chaykin LB, Courrèges JP, Handelsman Y, Lehmann LM, Mishra A, Simpson RW. The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial. Diabetes Ther. 2017 Feb;8(1):101-114. doi: 10.1007/s13300-016-0218-3. Epub 2016 Dec 10. PMID: 27943107; PMCID: PMC5306117.
Copy Download .nbib Format: NLM
Low kidney uptake of GLP-1R-targeting, beta cell-specific PET tracer, .

EJNMMI research

Mikkola K, Yim CB, Lehtiniemi P, Kauhanen S, Tarkia M, Tolvanen T, Nuutila P, Solin O.
PMID: 27957723
EJNMMI Res. 2016 Dec;6(1):91. doi: 10.1186/s13550-016-0243-2. Epub 2016 Dec 13.

BACKGROUND: Several radiometal-labeled, exendin-based tracers that target glucagon-like peptide-1 receptors (GLP-1R) have been intensively explored for β cell imaging. The main obstacle has been the high uptake of tracer in the kidneys. This study aimed to develop a novel...

Cite
Mikkola K, Yim CB, Lehtiniemi P, et al. Low kidney uptake of GLP-1R-targeting, beta cell-specific PET tracer, . EJNMMI Res. 2016;6(1):91doi: 10.1186/s13550-016-0243-2.
Mikkola, K., Yim, C. B., Lehtiniemi, P., Kauhanen, S., Tarkia, M., Tolvanen, T., Nuutila, P., & Solin, O. (2016). Low kidney uptake of GLP-1R-targeting, beta cell-specific PET tracer, . EJNMMI research, 6(1), 91. https://doi.org/10.1186/s13550-016-0243-2
Mikkola, Kirsi, et al. "Low kidney uptake of GLP-1R-targeting, beta cell-specific PET tracer, ." EJNMMI research vol. 6,1 (2016): 91. doi: https://doi.org/10.1186/s13550-016-0243-2
Mikkola K, Yim CB, Lehtiniemi P, Kauhanen S, Tarkia M, Tolvanen T, Nuutila P, Solin O. Low kidney uptake of GLP-1R-targeting, beta cell-specific PET tracer, . EJNMMI Res. 2016 Dec;6(1):91. doi: 10.1186/s13550-016-0243-2. Epub 2016 Dec 13. PMID: 27957723; PMCID: PMC5153397.
Copy Download .nbib Format: NLM
A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes.

Diabetes therapy : research, treatment and education of diabetes and related disorders

Webb N, Orme M, Witkowski M, Nakanishi R, Langer J.
PMID: 29574633
Diabetes Ther. 2018 Jun;9(3):973-986. doi: 10.1007/s13300-018-0397-1. Epub 2018 Mar 24.

INTRODUCTION: Semaglutide once-weekly (QW) is a novel glucagon-like peptide-1 (GLP-1) analogue administered at a 0.5 or 1.0 mg dose. In the absence of head-to-head trials between semaglutide QW and other GLP-1 receptor agonists (GLP-1 RAs) in a Japanese population,...

Cite
Webb N, Orme M, Witkowski M, et al. A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes. Diabetes Ther. 2018;9(3):973-986doi: 10.1007/s13300-018-0397-1.
Webb, N., Orme, M., Witkowski, M., Nakanishi, R., & Langer, J. (2018). A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes. Diabetes therapy : research, treatment and education of diabetes and related disorders, 9(3), 973-986. https://doi.org/10.1007/s13300-018-0397-1
Webb, Neil, et al. "A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes." Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 9,3 (2018): 973-986. doi: https://doi.org/10.1007/s13300-018-0397-1
Webb N, Orme M, Witkowski M, Nakanishi R, Langer J. A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes. Diabetes Ther. 2018 Jun;9(3):973-986. doi: 10.1007/s13300-018-0397-1. Epub 2018 Mar 24. PMID: 29574633; PMCID: PMC5984907.
Copy Download .nbib Format: NLM
Critical Management of Severe Hypotension Caused by Amlodipine Toxicity Managed With Hyperinsulinemia/Euglycemia Therapy Supplemented With Calcium Gluconate, Intravenous Glucagon and Other Vasopressor Support: Review of Literature.

Cardiology research

Kumar K, Biyyam M, Bajantri B, Nayudu S.
PMID: 29479386
Cardiol Res. 2018 Feb;9(1):46-49. doi: 10.14740/cr646w. Epub 2018 Feb 11.

Calcium channel blocker (CCB ) overdose, whether intentional or accidental, is a common clinical scenario and can be very lethal. Conventional treatments for CCB overdose include intravenous (IV) fluids, calcium salts, dopamine, dobutamine, norepinephrine, phosphodiesterase inhibitors, and glucagon. However,...

Cite
Kumar K, Biyyam M, Bajantri B, et al. Critical Management of Severe Hypotension Caused by Amlodipine Toxicity Managed With Hyperinsulinemia/Euglycemia Therapy Supplemented With Calcium Gluconate, Intravenous Glucagon and Other Vasopressor Support: Review of Literature. Cardiol Res. 2018;9(1):46-49doi: 10.14740/cr646w.
Kumar, K., Biyyam, M., Bajantri, B., & Nayudu, S. (2018). Critical Management of Severe Hypotension Caused by Amlodipine Toxicity Managed With Hyperinsulinemia/Euglycemia Therapy Supplemented With Calcium Gluconate, Intravenous Glucagon and Other Vasopressor Support: Review of Literature. Cardiology research, 9(1), 46-49. https://doi.org/10.14740/cr646w
Kumar, Kishore, et al. "Critical Management of Severe Hypotension Caused by Amlodipine Toxicity Managed With Hyperinsulinemia/Euglycemia Therapy Supplemented With Calcium Gluconate, Intravenous Glucagon and Other Vasopressor Support: Review of Literature." Cardiology research vol. 9,1 (2018): 46-49. doi: https://doi.org/10.14740/cr646w
Kumar K, Biyyam M, Bajantri B, Nayudu S. Critical Management of Severe Hypotension Caused by Amlodipine Toxicity Managed With Hyperinsulinemia/Euglycemia Therapy Supplemented With Calcium Gluconate, Intravenous Glucagon and Other Vasopressor Support: Review of Literature. Cardiol Res. 2018 Feb;9(1):46-49. doi: 10.14740/cr646w. Epub 2018 Feb 11. PMID: 29479386; PMCID: PMC5819629.
Copy Download .nbib Format: NLM
Single administration of vildagliptin attenuates postprandial hypertriglyceridemia and endothelial dysfunction in normoglycemic individuals.

Experimental and therapeutic medicine

Noguchi K, Hirota M, Miyoshi T, Tani Y, Noda Y, Ito H, Nanba S.
PMID: 25452780
Exp Ther Med. 2015 Jan;9(1):84-88. doi: 10.3892/etm.2014.2051. Epub 2014 Nov 05.

Postprandial hypertriglyceridemia impairs endothelial function and plays an important role in the development of atherosclerosis. The aim of the present study was to examine the postprandial effects of the dipeptidyl peptidase-4 inhibitor vildagliptin and the α-glucosidase inhibitor voglibose on...

Cite
Noguchi K, Hirota M, Miyoshi T, et al. Single administration of vildagliptin attenuates postprandial hypertriglyceridemia and endothelial dysfunction in normoglycemic individuals. Exp Ther Med. 2014;9(1):84-88doi: 10.3892/etm.2014.2051.
Noguchi, K., Hirota, M., Miyoshi, T., Tani, Y., Noda, Y., Ito, H., & Nanba, S. (2015). Single administration of vildagliptin attenuates postprandial hypertriglyceridemia and endothelial dysfunction in normoglycemic individuals. Experimental and therapeutic medicine, 9(1), 84-88. https://doi.org/10.3892/etm.2014.2051
Noguchi, Kaoru, et al. "Single administration of vildagliptin attenuates postprandial hypertriglyceridemia and endothelial dysfunction in normoglycemic individuals." Experimental and therapeutic medicine vol. 9,1 (2015): 84-88. doi: https://doi.org/10.3892/etm.2014.2051
Noguchi K, Hirota M, Miyoshi T, Tani Y, Noda Y, Ito H, Nanba S. Single administration of vildagliptin attenuates postprandial hypertriglyceridemia and endothelial dysfunction in normoglycemic individuals. Exp Ther Med. 2015 Jan;9(1):84-88. doi: 10.3892/etm.2014.2051. Epub 2014 Nov 05. PMID: 25452780; PMCID: PMC4247303.
Copy Download .nbib Format: NLM
Severe paraneoplastic hypoglycemia secondary to a gastrointestinal stromal tumour masquerading as a stroke.

Endocrinology, diabetes & metabolism case reports

Dimitriadis GK, Gopalakrishnan K, Rao R, Grammatopoulos DK, Randeva HS, Weickert MO, Murthy N.
PMID: 26535131
Endocrinol Diabetes Metab Case Rep. 2015;2015:150062. doi: 10.1530/EDM-15-0062. Epub 2015 Sep 21.

UNLABELLED: We report the case of a 70-year-old previously healthy female who presented acutely to the Accident and Emergency department with left-sided vasomotor symptoms including reduced muscle tone, weakness upon walking and slurred speech. Physical examination confirmed hemiparesis with...

Cite
Dimitriadis GK, Gopalakrishnan K, Rao R, et al. Severe paraneoplastic hypoglycemia secondary to a gastrointestinal stromal tumour masquerading as a stroke. Endocrinol Diabetes Metab Case Rep. 2015;2015:150062doi: 10.1530/EDM-15-0062.
Dimitriadis, G. K., Gopalakrishnan, K., Rao, R., Grammatopoulos, D. K., Randeva, H. S., Weickert, M. O., & Murthy, N. (2015). Severe paraneoplastic hypoglycemia secondary to a gastrointestinal stromal tumour masquerading as a stroke. Endocrinology, diabetes & metabolism case reports, 2015150062. https://doi.org/10.1530/EDM-15-0062
Dimitriadis, G K, et al. "Severe paraneoplastic hypoglycemia secondary to a gastrointestinal stromal tumour masquerading as a stroke." Endocrinology, diabetes & metabolism case reports vol. 2015 (2015): 150062. doi: https://doi.org/10.1530/EDM-15-0062
Dimitriadis GK, Gopalakrishnan K, Rao R, Grammatopoulos DK, Randeva HS, Weickert MO, Murthy N. Severe paraneoplastic hypoglycemia secondary to a gastrointestinal stromal tumour masquerading as a stroke. Endocrinol Diabetes Metab Case Rep. 2015;2015:150062. doi: 10.1530/EDM-15-0062. Epub 2015 Sep 21. PMID: 26535131; PMCID: PMC4629400.
Copy Download .nbib Format: NLM
Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors.

Clinical lipidology

Zhong J, Maiseyeu A, Rajagopalan S.
PMID: 26005496
Clin Lipidol. 2015;10(1):103-112. doi: 10.2217/clp.14.59.

Elevated post-prandial lipoprotein levels are common in patients with type 2 diabetes. Post-prandial lipoprotein alterations in type 2 diabetics are widely believed to drive inflammation and are considered a major risk factor for cardiovascular disease in diabetic patients. The...

Cite
Zhong J, Maiseyeu A, Rajagopalan S. Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors. Clin Lipidol. 2015;10(1):103-112doi: 10.2217/clp.14.59.
Zhong, J., Maiseyeu, A., & Rajagopalan, S. (2015). Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors. Clinical lipidology, 10(1), 103-112. https://doi.org/10.2217/clp.14.59
Zhong, Jixin, et al. "Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors." Clinical lipidology vol. 10,1 (2015): 103-112. doi: https://doi.org/10.2217/clp.14.59
Zhong J, Maiseyeu A, Rajagopalan S. Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors. Clin Lipidol. 2015;10(1):103-112. doi: 10.2217/clp.14.59. PMID: 26005496; PMCID: PMC4437760.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 3591 entries